Portal de Periódicos da CAPES

Soluble fibre (Plantago ovata husk) reduces plasma low-density lipoprotein (LDL) cholesterol, triglycerides, insulin, oxidised LDL and systolic blood pressure in hypercholesterolaemic patients: A randomised trial

2010; Elsevier BV; Volume: 211; Issue: 2 Linguagem: Inglês

10.1016/j.atherosclerosis.2010.03.010

1879-1484

Rosa Solà, Éric Bruckert, Rosa M. Valls, Silvia Narejos, Xavier Luque, Manuel Castro-Cabezas, Gema Doménech, Ferràn Torres, Mercedes Heras, Xavier Farrés, José-Vicente Vaquer, J Fausto Bustamante Martínez, Mari Cruz Almaraz, Anna Anguera,

Ginkgo biloba and Cashew Applications

Abstract The objective was to evaluate whether the soluble fibre Plantago ovata (Po)-husk improves cardiovascular disease (CVD) risk biomarkers including low-density lipoprotein cholesterol (LDL-C). Methods In a multi-centred, double-blind, placebo-controlled, parallel, randomised trial conducted in primary care-clinics in Spain, France and Holland, mild-moderate hypercholesterolaemic patients (age range: 43–67 years) received 14g/d of Po-husk ( n =126) or placebo (microcrystalline-cellulose 14g/d; n =128) in a low saturated fat diet for 8 weeks. Subsequently, if LDL-C remained ≥3.35mmol/L [130mg/dL], participants proceeded with the fibre plus simvastatin (20mg/d) for further 8 weeks. Lipid profile, blood pressure (BP), insulin, oxidised LDL and some gene polymorphisms involved in CVD risk were measured. Results Relative to placebo, Po-husk reduced plasma LDL-C by −6% ( P <0.0002), total cholesterol (TC) by −6%, triglycerides (TG) by −21.6%, apolipoprotein (Apo) B-100 by −6.7%, oxidised LDL by a mean of −6.82U/L (95%CI: 3.15–10.48), insulin by −4.68pmol/L (95%CI: 0.68–8.67) and systolic BP by −4.0mm Hg (95%CI; 1.2–6.7) ( P <0.05). The TG-lowering effect in the Po-husk group was magnified by variants in plasminogen-activator-inhibitor (PAI-1; rs1799768) and fatty acid-binding protein (FABP-2; rs1799883) genes. At 16 weeks, the intra-group action of simvastatin (20mg/d) added to Po-husk or placebo was a similar LDL-C reduction. Conclusions Po-husk, apart from lowering LDL-C, also reduced TG, TG related to certain gene variants, TC, Apo B-100, oxLDL, insulin-resistance and systolic BP in mild-moderate hypercholesterolaemic individuals. Thus, the target patients to receive Po-husk would be those who present a cluster of various CVD risk factors, such as metabolic syndrome.